Xiaoqian Xu

Xiaoqian Xu

Auto-generated profile, based on publicly available information

Xiaoqian Xu

National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University , Beijing 100050

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SHShangying Hu
Shangying Hu
XXXiaoqian Xu
Xiaoqian Xu
FZFengcai Zhu
Fengcai Zhu
YHYing Hong
Ying Hong
YHYuemei Hu
Yuemei Hu
FZFanghui Zhao
Fanghui Zhao
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unclear. This post-hoc analysis of a phase II/III study (NCT00779766) evaluated AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) VE against HR-HPV type infection in 871 Chinese women aged 18–25 years over a 72-month follow-up period. Study participants were DNA-negative at baseline to HR-HPV type(s) considered for VE and DNA-positive to any other HR-HPV type. Initial serostatus was not considered. Baseline DNA prevalence was 14.6% for any HR-HPV type and 10.6% excluding HPV-16/18. In the total vaccinated cohort for efficacy, VE against 6-month and 12-month HPV-16/18 persistent infections (PIs) in women DNA-negative to HPV-16/18 but DNA-positive to any other HR-HPV type at baseline was 100.0% (95% Confidence Interval [CI]: 79.8–100.0) and 100.0% (95%CI: 47.2–100.0), respectively. VE against HPV-16/18 incident infections in women DNA-positive to one vaccine type but DNA-negative to the other one at baseline was 66.8% (95%CI: −18.9–92.5). VE against HPV-31/33/45 incident infections, in women DNA-positive to HPV-16/18 and DNA-negative to the considered HPV type at baseline was 71.0% (95%CI: 27.3–89.8). No HPV-16/18 PIs were observed in vaccinated women with non-vaccine HPV A7/A9 species cervical infection at baseline. These findings indicated that women with existing HR-HPV infection at vaccination might still benefit from the AS04-HPV-16/18 vaccine. However, this potential benefit needs further demonstration in the future.

17 February 2024 in International Journal of Cancer
Verified
Journal Article
Closed access
TWTian‐Meng Wen
Tian‐Meng Wen
XXXiao‐Qian Xu
Xiao‐Qian Xu
XZXue‐Lian Zhao
Xue‐Lian Zhao
CPCheng‐Hao Pan
Cheng‐Hao Pan
YFYu‐Shu Feng
Yu‐Shu Feng
FZFanghui Zhao
Fanghui Zhao

1 July 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
XXXiaoqian Xu
Xiaoqian Xu
AWAndrea Woolner
Andrea Woolner
SBSohinee Bhattacharya
Sohinee Bhattacharya
SCSeonaidh Cotton
Seonaidh Cotton
FZFanghui Zhao
Fanghui Zhao
MCMargaret Cruickshank
Margaret Cruickshank

15 November 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JZJiayi Zhang
Jiayi Zhang
SCShuyan Chen
Shuyan Chen
JZJialing Zhou
Jialing Zhou
BWBingqiong Wang
Bingqiong Wang
XWXiaoning Wu
Xiaoning Wu
HYHong You
Hong You
Jiayi Zhang, Shuyan Chen, Jialing Zhou, Bingqiong Wang, Xiaoning Wu, Xiaoqian Xu, Xinyu Zhao, Yuanyuan Kong, Xiaojuan Ou, Yameng Sun, Hong You. Gut and Liver 2025;19:889-99. https://doi.org/10.5009/gnl250008

1 September 2025 in The Oncologist
Verified
Journal Article
Open access
XXXiao-Qian Xu
Xiao-Qian Xu
WLWei-Ming Li
Wei-Ming Li
LSLi-Chen Shi
Li-Chen Shi
HWHao Wang
Hao Wang
SLShun Li
Shun Li
YKYuanyuan Kong
Yuanyuan Kong
Importance: Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC). However, the clinical impact of temporary interruptions of Atez and Bev on treatment outcomes remains unclear. Objective: To evaluate the association between temporary interruptions of Atez or Bev and survival outcomes among patients with unresectable HCC. Design: Exploratory post hoc analysis of patient-level data from the phase 3 IMbrave150 (NCT03434379) trial. Setting: Global, multicenter, randomized phase 3 trial designed to evaluate the therapeutic benefit of Atez plus Bev compared with sorafenib in patients with unresectable HCC. Participants: A total of 251 patients with unresectable HCC who received Atez and Bev in the IMbrave150 trial. Exposures: Temporary interruptions of Atez or Bev during treatment. Main Outcomes and Measures: Overall survival (OS) and progression-free survival (PFS). Results: Among 251 patients treated with Atez/Bev, 79 (31.5%) experienced Atez interruptions and 86 (34.3%) had Bev interruptions. Interruptions were not significantly associated with OS (HR = 1.57, 95% CI: 0.90-2.73 for Atez, HR = 0.50, 95% CI: 0.16-1.53 for Bev). However, both were significantly associated with improved PFS (HR = 0.56, 95% CI: 0.34-0.92 for Atez and HR = 0.61, 95% CI: 0.39-0.94 for Bev). Subgroup analyses showed that positive association of PFS and interruptions was primarily observed in patients with events or treatment duration <12 months. Early (within 6 months) and late interruptions (after 6 months) showed trends toward longer PFS but were not statistically significant (HR = 0.56, 95% CI: 0.27-1.15 and HR = 0.57, 95% CI: 0.29-1.09 for Atez, HR = 0.61, 95% CI: 0.37-1.02, and HR = 0.60, 95% CI: 0.29-1.27 for Bev). Conclusions and Relevance: In this exploratory analysis, temporary interruptions of Atez or Bev were not associated with worse survival outcomes in patients with unresectable HCC. Prospective studies are needed to validate these findings.

1 July 2025 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
XXXiao Qian Xu
Xiao Qian Xu
HWHao Wang
Hao Wang
LSLi Chen Shi
Li Chen Shi
CHCheng Huang
Cheng Huang
HYHong You
Hong You
YKYuanyuan Kong
Yuanyuan Kong